Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Article content
BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice ® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies.
Article content
RenMab™ mice are a core member of Biocytogen's independently developed RenMice ® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE ®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process.
Article content
With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite ® /RenNano ® /RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value.
Article content
With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice ® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide.
Article content
About Biocytogen
Article content
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
Article content
Article content
Article content
Contacts
Article content
Biocytogen Contacts
Article content
Article content
Antibody assets and platforms:
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Should You Invest $1,000 in Taiwan Semiconductor Stock Today?
During the month of May, stocks started exhibiting some much-needed resilience. The S&P 500 and Nasdaq Composite indexes rose by 5% and 8%, respectively. After bearing the brunt of precipitous sell-offs early this year, semiconductor stocks have started to stage a comeback. Last month, shares of Nvidia and Broadcom climbed by more than 20%, while Advanced Micro Devices surged by roughly 15%. Lagging behind the usual suspects, however, was Taiwan Semiconductor Manufacturing (NYSE: TSM). While the stock's 12% gains beat the broader market, they still trail the chip industry's leading names. Below, I'll delve into why Taiwan Semi looks like a great buy right now. From there, I'll illustrate how a $1,000 investment could wind up being a multibagger for patient, disciplined investors. A hidden gem in a sea of semiconductor stocks Nvidia and AMD design chipsets known as graphics processing units (GPU). GPUs have the capability to run sophisticated calculations at fast speeds, which gives them an edge over traditional compute processes when it comes to developing generative AI applications. Cloud hyperscalers such as Microsoft, Alphabet, and Amazon, as well as big tech giants Meta Platforms and Oracle, have been buying GPUs in droves over the last few years in an effort to build out data centers and infrastructure services. While the robust demand for chips directly benefits Nvidia and AMD, Taiwan Semi has been an indirect beneficiary of these tailwinds. The reason? Because Taiwan Semi specializes in foundry services that actually manufacture the chip designs from Nvidia, AMD, and many others. In other words, the largest data center businesses in the world rely heavily on Taiwan Semi's fabrication business. Taiwan Semi is positioned for monster growth In the chart below, I've illustrated Taiwan Semi's revenue, gross profit, and net income over the last three years. As the slopes of the lines indicate, TSMC's sales and profitability profile are both steepening. TSM Revenue (TTM) data by YCharts To me, this signals two things. First, demand for chips is on the rise -- hence the revenue line is rising. However, the more lucrative trend is that gross margin and net income are accelerating in parallel with sales. This suggests that Taiwan Semi has achieved a fair degree of pricing power relative to competitors such as Intel. Considering AI infrastructure spend is expected to eclipse multiple trillions over the next five years, I don't see Taiwan Semi's growth prospects decelerating anytime soon. Should you invest $1,000 in TSMC stock? It's worth noting that technology investors Cathie Wood and Stanley Druckenmiller each recently added Taiwan Semi stock to their firms' respective portfolios. While blindly following institutional capital flows isn't necessarily a prudent strategy, I do think TSMC's long-term prospects earn some more credibility thanks to the recent buys by such prominent investors. In the chart below, I've illustrated how a $1,000 investment in Taiwan Semi stock 10 years ago is now worth approximately $8,500. Achieving almost a tenfold return in 10 years is impressive -- even for a growth stock. TSM data by YCharts There are a couple of important ideas to take away from the chart above. First, the trends clearly show that like many of its peers, TSMC stock has kicked into a new gear over the last couple of years thanks to a bullish AI narrative. Hence, the share price gains following the sell-off in 2022 appear overly pronounced. Here's the thing, though: Had you invested $1,000 in Taiwan Semi stock on Nov. 30, 2022 (the day ChatGPT was commercially launched), you would have doubled your money. This underscores the idea that holding on to a stock for long-term periods (i.e. 10 years or more) can lead to outsized gains compared to shorter-term, volatile periods. I think now is a great time to invest $1,000 in Taiwan Semi stock. The company's future growth prospects are arguably far more robust than they were 10 years ago, making now an interesting time to begin accumulating shares for a long-run position. Should you invest $1,000 in Taiwan Semiconductor Manufacturing right now? Before you buy stock in Taiwan Semiconductor Manufacturing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Meta Platforms, Microsoft, Nvidia, Oracle, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
3 hours ago
- Globe and Mail
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market uncertainties and a volatile macroeconomic environment. The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets. Though the massive tariffs imposed by the United States and China are now on a pause, it is only a temporary suspension, and no one knows what will happen after the 90-day tariff suspension ends. The uncertainty around tariffs and trade production measures remains, slowing down economic growth. Although pharmaceuticals have been exempted from tariffs in the first round, they could be Trump's target in the next round, considering the President's goal to shift pharmaceutical production back to the United States, primarily from European and Asian countries. Trump and the Republican government also continue to stress on the control of drug prices with the latest attempt being his 'most favored nations' policy.' Let's understand AZN's strengths and weaknesses to better analyze how to play the stock in an uncertain macro environment. AZN's Strong Portfolio of Blockbuster Drugs AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines. AstraZeneca now has 16 blockbuster medicines in its portfolio with sales exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza (partnered with Merck [ MRK ]), Calquence and Ultomiris. These drugs are driving the company's top line, backed by increasing demand trends. The company is confident that the growth will continue in 2025. Almost every new product it has launched in recent years has done well. Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap are also expected to continue to contribute to top-line growth in 2025. AZN Enjoys Strong Position in the Oncology Space Oncology is AstraZeneca's biggest segment. The company is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Oncology sales (comprising around 41% of AstraZeneca's total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales. The strong oncology performance is being driven by medicines such as Tagrisso, Merck-partnered Lynparza, Imfinzi, Calquence and Daiichi Sankyo-partnered Enhertu. A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $430 million in 2024 and $132 million in the first quarter of 2025. In January this year, AstraZeneca and partner Daiichi's drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer, while a regulatory application is under review for EGFR-mutated non-small cell lung cancer (NSCLC). Datroway witnessed encouraging early launch signals in the United States. AstraZeneca expects continued growth of its oncology medicines in 2025, particularly Tagrisso, Enhertu and Imfinzi, despite the incremental impact of the Part D redesign. Several Headwinds to Hurt AZN's Top Line in 2025 The impact of Part D redesign hurt sales of AZN's older drugs, Tagrisso, Lynparza and Ultomiris, as well as newer drugs, Truqap and Wainua, in the United States in the first quarter of 2025, with the trend expected to continue through the rest of the year. AstraZeneca expects Farxiga and Lynparza to be included in the volume-based procurement plans in China in mid-2025, which can hurt sales of these drugs in the country. Pricing and competitive pressure in Europe and generic competition in some emerging markets are expected to hurt sales of some drugs. Brilinta generics are expected to be launched in the United States in 2025. This will hurt sales of the drug. Biosimilar versions of Soliris were launched in the United States in March 2025, which, along with successful conversion to Ultomiris, biosimilar pressure in Europe and unfavorable order timing in certain tender markets, is expected to lead to a continuous decline in sales of Soliris. AstraZeneca is facing ongoing investigations at its China subsidiary. The Chinese authorities are investigating some current and former AstraZeneca employees at its China subsidiary for medical insurance fraud, illegal drug importation and personal information breaches. AZN Stock's Price, Valuation & Estimates AZN stock has risen 8.2% so far this year againsta decrease of 3.1% for the industry. The stock has also outperformed the sector and S&P 500 index, as seen in the chart below. AZN Stock Outperforms Industry, Sector & S&P 500 From a valuation standpoint, AstraZeneca is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 14.93 forward earnings, slightly higher than 14.74 for the industry. However, AZN's stock is trading below its 5-year mean of 18.05. The stock is also much cheaper than other large drugmakers like Eli Lilly LLY and Novo Nordisk NVO. Eli Lilly and Novo Nordisk currently dominate the obesity space. AZN Stock Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $4.47 per share to $4.50 per share over the past 60 days. For 2026, earnings estimates have risen from $4.95 per share to $4.98 per share over the same timeframe. AZN Estimate Movement Consider Buying AZN Stock Despite the potential impact from Part D redesign, AstraZeneca expects total revenues to grow by a high single-digit percentage at CER in 2025. Growth momentum in Oncology and CVRM(cardiovascular, renal and metabolism) segments is expected to continue in 2025. However, in Rare Disease, though AstraZeneca expects growth in 2025, it will be at a slower pace than in 2024. Regarding the potential impact of tariffs, AstraZeneca had a positive tone on the first-quarter conference call. The company said it has limited commercialized finished medicines imported to the United States from China, which lowers its exposure to potential China tariffs on pharmaceuticals. It also has a substantial and growing manufacturing footprint in the United States, and the majority of its medicines sold in the United States are manufactured domestically. It does import some medicines from Europe but believes that if tariffs on pharmaceutical imports from Europe are implemented in a similar range as other industries, it will be manageable and allow the company to remain within its guidance range for EPS. In 2025, AstraZeneca expects core EPS to increase by a low double-digit percentage. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. AstraZeneca expects to generate$80 billion in total revenues by 2030, a significant increase from the $54 billion it generated in 2024. By the said time frame, AstraZeneca plans to launch 20 new medicines, with nine new medicines already launched/approved. It believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. The company is also on track to achieve a mid-30s percentage core operating margin by 2026 Considering AZN's growth prospects, investors may take advantage of the recent dip and consider buying this Zacks Rank #2 (Buy) stock, more so as it is trading below its five-year mean. Consistently rising estimates also indicate analysts' optimistic outlook for growth. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report
Globe and Mail
4 hours ago
- Globe and Mail
Why Is Everyone Talking About Coupang's Stock?
Coupang (NYSE: CPNG) may not be a well-known company in the U.S., but it has certainly captured the hearts of consumers in South Korea, growing over the years to become the top e-commerce company in its home market. Coupang's solid performance has captured the attention of sharp-eyed investors, which explains its respectable 25% increase in stock price in the last 12 months (as of this writing). Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » This article will delve deeper into the company and explore why investors are excited about it. The Amazon of South Korea and beyond Amazon has arguably been the most successful e-commerce company over the last two decades, leading to numerous clones attempting to replicate its business model in their respective markets. Most either don't perform well or fail outright, except for a handful, such as in China and Coupang in South Korea. Inspired by Amazon's customer obsession, Coupang strives to please its customers continually. One way is to provide a wide selection of products to customers, delivered at breathtaking speeds via its extensive in-house warehouse and logistics infrastructure. For instance, consumers can order fresh groceries and millions of other general merchandise items by midnight and receive products by 7 a.m. the next morning. If customers are unhappy with the products, they can tap a button on the app and leave the item outside their door for pickup -- refunds will be processed immediately after pickup. But that's just one part of the story. Coupang's efforts to delight its users have expanded far beyond their roots into other areas, including food delivery, online streaming, and services such as free appliance and furniture installations. Customers are eligible for all these perks for free if they join the Wow membership program. Unsurprisingly, customers love this approach, which explains Coupang's leading market share of 25% in South Korea. Coupang's success in South Korea has also prompted the company to expand into new geographies, such as Taiwan, and new business segments via the acquisition of Farfetch. While these new business additions will take time to bear fruit, they will open up new growth avenues for the e-commerce company. Coupang is executing well lately Coupang is also delivering solid growth. For the year ended Dec. 31, revenue surged by 24% (or 29% on an currency-neutral basis) to $30.3 billion on the back of growth in its e-commerce business and the acquisition of Farfetch. Coupang's growth continued into 2025, with revenue growing at 11% (or 21% on an currency-neutral basis ) to $7.9 billion. Top-line growth is just one part of the story. Coupang has gradually improved its margins over time, with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margins improving from 3.9% to 4.8% in the last five quarters. The tech company targets adjusted EBITDA margins to exceed 10% in the long run, suggesting that there is still considerable room for improvement. In short, while Coupang is already generating tens of billions in revenue, it is well-positioned to sustain its growth momentum, leveraging its world-class infrastructure, vast customer base, and customer-obsessed culture. Coupang authorized a $1 billion share buyback plan Coupang's recent share buyback plan is a significant milestone for several reasons. One, it suggests that Coupang has evolved from a high-growth, loss-making company to one that's growing more sustainably and responsibly. To the extent that it can return excess cash to shareholders, such a move also signals the company's confidence in its future, suggesting that management may view the shares as undervalued compared to the company's prospects. Additionally, with ample cash on its balance sheet ($6.1 billion in cash and cash equivalents, as of the time of writing), management's share buyback plan demonstrates its discipline in capital allocation, which complements its other investments in growth and innovation. It also suggests that management has a clear strategy for capital allocation, which is likely to enhance long-term shareholder value. What it means for investors Coupang is a rare example of a successful Amazon clone that has achieved excellent outcomes. While continuing to execute its expansion strategy, Coupang is also on track to return excess cash to shareholders through share buybacks. Investors seeking to diversify their stock holdings beyond the U.S. may want to keep this company under their radar. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $363,030!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,088!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $674,395!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon. See the 3 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Lawrence Nga has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon. The Motley Fool recommends Coupang and The Motley Fool has a disclosure policy.
